Q32 BIO INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2015-01-01

Employees: 101

Market Cap: -

Website: http://www.homologymedicines.com

Clinical Trials

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants with IgAN, LN or C3G

Phase 2

Recruiting

Conditions: Lupus Nephritis (LN)
C3 (Complement Component 3) Glomerulopathy
IgA Nephropathy

Interventions: Drug: ADX-097

First Posted Date: 2024-05-17

Last Posted Date: 2024-12-19

Lead Sponsor: Q32 Bio Inc.

Target Recruit Count: 30

Registration Number: NCT06419205

Locations: 🇺🇸
Denver, Denver, Colorado, United States
🇺🇸
Minneapolis, Minneapolis, Minnesota, United States
🇺🇸
Las Vegas, Las Vegas, Nevada, United States

and more 2 locations

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata

Phase 2

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: ADX-914
Drug: Placebo

First Posted Date: 2023-08-30

Last Posted Date: 2024-05-10

Lead Sponsor: Q32 Bio Inc.

Target Recruit Count: 40

Registration Number: NCT06018428

Locations: 🇺🇸
Mayfield Heights, Ohio, Mayfield Heights, Ohio, United States
🇺🇸
Scottsdale, Arizona, Scottsdale, Arizona, United States
🇺🇸
Fayetteville, Arkansas, Fayetteville, Arkansas, United States

and more 20 locations

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Phase 2

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: ADX-914

First Posted Date: 2022-08-19

Last Posted Date: 2024-10-03

Lead Sponsor: Q32 Bio Inc.

Target Recruit Count: 102

Registration Number: NCT05509023

Locations: 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
🇺🇸
Dermatology of Seattle & Bellevue, Seattle, Washington, United States
🇺🇸
Dermatology Specialists of Spokane, Spokane, Washington, United States

and more 21 locations

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Phase 1

Withdrawn

Conditions: Mucopolysaccharidosis II

Interventions: Biological: Genetic HMI-203

First Posted Date: 2022-02-14

Last Posted Date: 2023-08-28

Lead Sponsor: Homology Medicines, Inc

Registration Number: NCT05238324

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia, United States
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 3 locations

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

Phase 1

Terminated

Conditions: Phenylketonurias
Phenylketonuria
PAH Deficiency

Interventions: Drug: HMI-103

First Posted Date: 2022-02-03

Last Posted Date: 2023-10-10

Lead Sponsor: Homology Medicines, Inc

Target Recruit Count: 3

Registration Number: NCT05222178

Locations: 🇺🇸
The Community Health Clinic, Topeka, Indiana, United States
🇺🇸
Clinic for Special Children, Lancaster, Pennsylvania, United States

Natural History Clinical Study in Adult PKU

Terminated

Conditions: Phenylketonurias
PKU

First Posted Date: 2021-02-24

Last Posted Date: 2023-08-25

Lead Sponsor: Homology Medicines, Inc

Target Recruit Count: 7

Registration Number: NCT04768348

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

and more 5 locations

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Safety Issues

Interventions: Drug: ADX-914
Drug: Placebo

First Posted Date: 2020-07-24

Last Posted Date: 2022-07-28

Lead Sponsor: Q32 Bio Inc.

Target Recruit Count: 42

Registration Number: NCT04485481

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Conditions: Phenylketonuria
PAH Deficiency

Interventions: Genetic: HMI-102

First Posted Date: 2020-04-16

Last Posted Date: 2022-06-30

Lead Sponsor: Homology Medicines, Inc

Target Recruit Count: 21

Registration Number: NCT04348708

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

Gene Therapy Clinical Study in Adult PKU

Phase 1

Terminated

Conditions: Phenylketonurias
PAH Deficiency

Interventions: Genetic: HMI-102

First Posted Date: 2019-05-16

Last Posted Date: 2023-08-29

Lead Sponsor: Homology Medicines, Inc

Target Recruit Count: 10

Registration Number: NCT03952156

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
The University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States

and more 10 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy